Fibroblast activation protein inhibitor
By designing the compound XmYnZp to bind to radionuclides, the enrichment and retention of tumor sites is enhanced, and the problem of short retention time of existing FAPI small molecule drugs in tumor tissues is solved, achieving more efficient tumor treatment effects.
WO2025167951A1 Publication Date: 2025-08-14BOOMRAY PHARMACEUTICALS CO LTD
15 Cites 1 Cited by
Patent Information
- Application Number
- PCT/CN2025/075914
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-08-09
- Filing Date
- 2025-02-06
- Publication Date
- 2025-08-14
AI Technical Summary
Technical Problem
The existing FAPI small molecule radioactive drugs have a short retention time in tumor tissue, resulting in low tumor absorption rate, limiting their application in tumor treatment.
Method used
A compound XmYnZp is designed with a specific chemical structure for binding to radionuclides, enhancing enrichment and retention at tumor sites, and achieving targeted treatment by specific binding to tumor cells with high expression of fibroblast activation protein (FAP).
Benefits of technology
It improves the drug retention time in tumor tissue, enhances the tumor treatment effect, improves the tumor absorption rate, and improves the treatment effect.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention relates to a fibroblast activation protein inhibitor, a pharmaceutical composition comprising the compound, and a use thereof in the diagnosis or treatment of fibroblast activation protein overexpression diseases.
Need to check novelty before this filing date? Find Prior Art